An industry with great demand and seemingly stagnated development, no approvals have been granted within the Post Traumatic Stress Disorder (PTSD) space for 25 years. Current statistics indicate that 4% of the population deal with PTSD worldwide, and this average is greater for those in the US at 7%. For PTSD the FDA has currently approved two SSRI’s including sertraline and paroxetine.
Looking at the world of psychedelics, the use of MDMA was both considered and tested as a potential new PTSD...